How Bimzelx Targets IL-17 Differently
Bimzelx (bimekizumab) is a monoclonal antibody that binds to both IL-17A and IL-17F isoforms, fully blocking both cytokines. Other IL-17 inhibitors target only IL-17A: Cosentyx (secukinumab) binds IL-17A alone, and Taltz (ixekizumab) binds it with higher affinity but ignores IL-17F. Dual inhibition reduces inflammation more comprehensively in psoriasis and psoriatic arthritis, as IL-17F contributes independently to skin and joint damage.[1][2]
Dosing Schedule Compared to Cosentyx and Taltz
Bimzelx requires injections every 8 weeks after initial loading doses (330 mg at weeks 0, 4, 8, 12, 16), easing patient burden. Cosentyx uses every 4 weeks (300 mg), and Taltz every 4 weeks (80 mg). Fewer doses improve adherence, with studies showing similar or better efficacy for Bimzelx in plaque psoriasis clearance.[3]
Efficacy Head-to-Head in Psoriasis Trials
In phase 3 trials like BE VIVID and BE READY, 85-91% of Bimzelx patients achieved PASI 90 (90% skin clearance) at week 16, outperforming Cosentyx (50-59%) and matching or exceeding Taltz in head-to-head data. For psoriatic arthritis, Bimzelx showed stronger joint and skin responses in BE OPTIMAL, resolving enthesitis faster than Cosentyx.[1][4]
Approved Uses: Where Bimzelx Expands Options
Bimzelx is FDA-approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and non-radiographic axial spondyloarthritis. Cosentyx covers similar plus ankylosing spondylitis and hidradenitis suppurativa; Taltz adds ankylosing spondylitis but not axial SpA subtypes. Bimzelx's broader IL-17 blockade supports its use in IL-17-driven conditions without overlapping approvals yet.[2]
Safety Profile: Similar Risks, Watch IL-17F Effects
All share fungal infection risks (e.g., candidiasis) from IL-17 blockade, with Bimzelx rates comparable (7-16% oral candidiasis). Dual inhibition may increase mild infections slightly, but serious adverse events match competitors (4-7%). No new safety signals in trials up to 2.5 years.[3][4]
Who Makes Bimzelx and Patent Timeline
UCB Pharma developed and markets Bimzelx, launched in 2023. Key patents expire around 2035-2037 per DrugPatentWatch, later than Cosentyx (2032) and Taltz (2034), delaying biosimilars.[5]
[1] NEJM: Bimekizumab versus Secukinumab (2021)
[2] FDA Labels: Bimzelx, Cosentyx, Taltz
[3] Lancet: BE COMPLETE PsA Trial (2022)
[4] Annals Rheum Dis: BE OPTIMAL (2023)
[5] DrugPatentWatch.com: Bimzelx Patents (hyperlink: https://www.drugpatentwatch.com/p/tradename/BIMZELX)